European Commission Grants Conditional Clearance to Remdesivir

The European Commission has granted a conditional clearance to use Gilead Sciences’ Remdesivir to treat Covid-19

This decision came after the European Medicines Agency’s “rolling review” that started at the end of April.

The Commission had previously stated that it was negotiating with Gilead to purchase sufficient doses for European Union members.

Meanwhile, “under the authorization, Remdesivir is indicated for the treatment of COVID-19 in adults and adolescents with pneumonia requiring supplemental oxygen,” Gilead Sciences said in a statement.